Copper-free ‘click’ chemistry-based synthesis and characterization of carbonic anhydrase-IX anchored albumin-paclitaxel nanoparticles for targeting tumor hypoxia

International Journal of

Molecular Sciences

Article

Copper-Free ‘Click’ Chemistry-Based Synthesis and

Characterization of Carbonic Anhydrase-IX Anchored

Albumin-Paclitaxel Nanoparticles for Targeting

Tumor Hypoxia

Katyayani Tatiparti ¹^,^†, Samaresh Sau ¹^,*^,^†, Kaustubh A. Gawde ¹and Arun K. Iyer ¹^,²^,* ^I ^D

ID

1

Use-Inspired Biomaterials & Integrated Nano Delivery (U-BiND) Systems Laboratory, Department of

Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State

University, Detroit, MI 48201, USA; katyayani.tatiparti@wayne.edu (K.T.);

kaustubhagawde@gmail.com (K.A.G.)

2

Molecular Imaging Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of

Medicine, Detroit, MI 48201, USA

*

Correspondence: samaresh.sau@wayne.edu (S.S.); arun.iyer@wayne.edu (A.K.I.); Tel.: +1-313-577-3220 (S.S.);

1-313-577-5875 (A.K.I.)

These authors contributed equally to this work.

+

†

Received: 9 January 2018; Accepted: 5 March 2018; Published: 13 March 2018

Abstract: Triple negative breast cancer (TNBC) is a difﬁcult to treat disease due to the absence

of the three unique receptors estrogen, progesterone and herceptin-2 (HER-2). To improve the

current therapy and overcome the resistance of TNBC, there is unmet need to develop an effective

targeted therapy. In this regard, one of the logical and economical approaches is to develop a tumor

hypoxia-targeting drug formulation platform for selective delivery of payload to the drug-resistant

and invasive cell population of TNBC tumors. Toward this, we developed a Carbonic Anhydrase

IX (CA IX) receptor targeting human serum albumin (HSA) carriers to deliver the potent anticancer

drug, Paclitaxel (PTX). We used Acetazolamide (ATZ), a small molecule ligand of CA IX to selectively

deliver HSA-PTX in TNBC cells. A novel method of synthesis involving copper free ‘click’ chemistry

(

Dibenzocyclooctyl, DBCO) moiety with an azide-labeled reaction partner, known as Strain-Promoted

Alkyne Azide Cycloaddition (SPAAC) along with a desolvation method for PTX loading were used in

the present study to arrive at the CA IX selective nano-carriers, HSA-PTX-ATZ. The anticancer effect

of HSA-PTX-ATZ is higher compared to HSA, PTX and non-targeted HSA-PTX in MDA-MB-231 and

MDA-MB-468 cells. The cell killing effect is associated with induction of early and late phases of

apoptosis. Overall, our proof-of-concept study shows a promising avenue for hypoxia-targeted drug

delivery that can be adapted to several types of cancers.

Keywords: carbonic anhydrase IX; tumor hypoxia targeting; paclitaxel; copper free ‘click’ chemistry;

triple negative breast cancer; albumin nanoparticles; human serum albumin

1

. Introduction

Cancer is a one the major causes of death in the U.S.A., annually claiming more than half a

million lives and an estimated 1.5 million new cases [1]. Thus, there is an urgent need to improve

diagnostic tools for early detection and to develop more selective drug delivery agents for therapy of

cancer with least toxic side effects. Nanomedicines have been shown to be multitasking drug delivery

vehicles that can passively accumulate within tumor tissue and have been clinically approved for

conventional cancer therapy. Accumulated evidence indicates that current drug delivery agents failed

in clinical trials due to lack of targeting ability, poor tumor penetration, tumor heterogeneity, and

Int. J. Mol. Sci. 2018, 19, 838; doi:10.3390/ijms19030838

www.mdpi.com/journal/ijms

Int. J. Mol. Sci. 2018, 19, 838

2 of 21

complex association of tumor associated immune cells and stroma [2]. Thus, targeted drug delivery

that utilizes various ligands to recognize speciﬁc biomarkers expressed on tumor components has

become extremely important in selective delivery of drugs and enhancing therapeutic efﬁcacy [3–16].

The targeted cancer treatment approach differentiates between healthy and cancer tissues [17,18].

One smart way of designing a successful approach for tumor targeting can be the development of

tumor multi-component targeting ligand library, and formulations with various types of biocompatible

drug-carriers. This library of ligands could be surface decorated with drug-carrier systems using

a combinatorial reagent-free organic synthesis approach for improving tumor early diagnosis and

therapy. Modern research methods have the potential to transform personalized cancer treatment with

improved quality of life, while providing the opportunity to integrate chemistry, drug delivery, cancer

research elements and discoveries into multidisciplinary research experiences. The research presented

in this study is based on a similar idea, i.e.,

(

i) self-assembling of polymer, lipid, metallic-based nanosized drug-carrier, and bio-manufacturing

of endogenous cell- (red blood cell, exosome) and protein (serum albumin, transferrin)-based

cargo carrier [3,6,8,19–33];

(

ii) functionalization of targeting ligands with the cargo carriers using a reagent-free synthesis

approach, such as copper free cyclic Alkyne-Azide click reaction, “Thiol-Ene” Michael-type, and

strain-promoted “Alkyne-Nitrone” cycloadditions [34–43].

The beauty of all these reactions is that they do not require any harmful chemicals, reagents, or

any special condition, and they yield highly speciﬁc coupled products. The new knowledge gained

through this interdisciplinary effort will provide a unique repertoire of advancement in drug delivery

with rational design of targeting ligand-customized cargo carriers to exert distinct functions in the

tumor microenvironment. The present study is an attempt to apply this simple strategy to develop a

formulation of human serum albumin (HSA) via the copper-free cyclic Alkyne-Azide click reaction

that targets tumor hypoxia.

Furthermore, nanoparticles have been broadly utilized as drug delivery systems for targeted

delivery of anticancer drugs [44–64] in the pharmaceutical industry. They can enhance the delivery of

hydrophobic drugs, decrease metabolic degradation of these drugs, target their delivery to malignant

cancer cells just by the alteration of the surface of the delivery system with the addition of a ligand,

and show controlled, extended or sustained delivery of drugs [7,8,13,25,53,58,65–81]. Alongside

the capacity to improve the solubility of hydrophobic drugs, nanomicelles additionally can target

cancer cells by two different strategies: passive and active targeting. The passive targeting delivery

systems rely on the capacity of nanomicelles to exploit the Enhanced Permeability and Retention (EPR)

effect [61

improvement of profoundly disordered and ﬂawed veins. Hence, nanoparticles including nanomicelles

can extravasate and gather at the tumor site [89 90]. Hence, the nanomicelles are commonly conjugated

,82–88]. The EPR phenomenon proposes that the multiplication of cancer cells brings about the

,

with a targeting moiety in the targeted delivery system, thus, encouraging the speciﬁc aggregation of

the drugs in target tissues, singular cancer cells, or intracellular organelles that are related to speciﬁc

targeting biomarkers in cancer cells [83

to all cancer cells and, in some, may not be as effective as in others [86

,

84]. However, the presence of the EPR effect is not common

91]. Further, in those cancer

,

cells that do show the EPR effect, angiogenesis is not uniform across the tumor depth which can

cause unequal distribution of the drugs. This gives a reason to develop targeted delivery systems that

function via active uptake by the cancer cells via receptor-mediated cell uptake [92]. The present study

is one such attempt.

Albumin is the most inexhaustible plasma protein in the human body. Its anti-immunogenic

properties make albumin a favored component as a sole carrier or a component of a carrier system for

an assortment of cancer medications. Like the vast majority of plasma proteins, albumin is produced

in the liver where it is created at a rate of around 0.7 mg/h for each gram of liver (i.e., 10–15 g daily).

The normal half-life of albumin is 19 days. Its high take-up in inﬂamed and tumor cells makes it

Int. J. Mol. Sci. 2018, 19, 838

3 of 21

a perfect carrier for medications to target malignant cells. Numerous research- and industry-based

techniques have been mentioned for in the literature, which conjugate or encapsulate different

medications to albumin. Human serum albumin protein has a total set of 585 amino acids. A solitary

polypeptide chain comprises 17 disulﬁde bonds, one free thiol and one tryptophan functional groups

which make it an effective binding protein [93]. The advantages of the human serum albumin (HSA)

include the presence of several drug binding sites like the amino and carboxylic groups that provide

opportunities for covalent modiﬁcations and drug or protein attachment of the drugs or targeting

ligands [94

been applied as a matrix for nanoparticles-based drug delivery systems [97

property that makes it preferable as a drug delivery carrier may be the fact that it is not susceptible to

opsonization by serum proteins [100 101]. HSA conjugation could provide nanoparticles that are a

promising delivery system for biopharmaceutically challenging medications, for example Paclitaxel

PTX), and they enhance the medication delivery and bioavailability for such drugs [102,103].

Carbonic Anhydrase (CA) is a zinc metalloenzyme that converts CO to bicarbonate reversibly

–

96]. It has low-cost, non-immunogenic and naturally biodegradable properties that have

–

99]. The most important

,

(

2

generating a proton in the process. There are about 15 varieties of CAs in mammals each of which

exhibit different properties, but all of them are involved in ion exchange and pH balance [104]. Of all of

them, CA IX is the most efﬁcient and is available on the surface of cancer cells. The enzyme’s active site

is exposed outside the cell membrane. It is not expressed in normal healthy cells but is overexpressed

in cancer cells under the inﬂuence of hypoxia [80

fast-growing tumor cells which outgrow the oxygen supply creating a scenario of hypoxia. Thus, it

has become the primary target for cancer therapy [106 108]. Sulfonamides are a group of anti-bacterial

agents that have been recently proven to have antitumor activity too [109 110]. Acetazolamide (ATZ)

,105], that is in turn produced by the extensively and

–

,

is an aromatic member of the family of sulfonamides that is different from the other members of the

group in that it does not have antibacterial properties. It was used for glaucoma and epilepsy but has

also been proven to have carbonic anhydrase inhibitory activity. It has been used as an antitumor agent

for 40 years. Other aromatic sulfonamides have also been found to have antitumor activities [111,112].

Paclitaxel is an effective anticancer drug used for chemotherapy. It has a unique chemical

structure and results in polymerization of tubulin to stabilize microtubules and, furthermore, associates

speciﬁcally with microtubules, making them stable against depolymerization in the presence of calcium

and at cold temperatures, which otherwise promptly depolymerize ordinary microtubules. It is

also known to act against mitochondria and inhibit apoptosis inhibitor protein B-cell Leukemia 2

(

Bcl-2) [113–117]. However, it is highly hydrophobic and needs to be delivered via a delivery system

that improves its solubility and delivers it at the target sites [16].

The research described in this article is one such attempt to design a targeted delivery system

to deliver Paclitaxel to triple negative breast cancer (TNBC) cancer cell lines and test its efﬁcacy

in vitro. The results show a promising avenue for targeted delivery that can be adapted to several

types of cancers.

2

. Results

2

.1. Synthesis of the Hypoxia Targeting Drug Delivery System

The product was prepared as described in Section 4.1. The ﬁnal formulation was dialyzed and

lyophilized to form a powder. The resultant product was then analyzed by FTIR (Fourier-transform

infrared spectroscopy) to conﬁrm the presence of the components used and the formation of the

product from click reaction. The results of FTIR (Figure S1) showed characteristic peaks between

−

1

−

+

−

1

700–2100 cm corresponding to the N== N== N (azide) stretching and there is an observable

shift in the peaks that indicates that the reaction has occurred. It also shows peaks for –N–H, –C=O,

−

1

and –C–H bond stretching at 3300–3500, 1670–1820, and 1050–1350 cm respectively. These results

1

were further conﬁrmed by H NMR spectrum (Figure S2) that show peaks between 6.8–7.4 ppm that

Int. J. Mol. Sci. 2018, 19, 838

4 of 21

correspond to the hydrogens of the Dibenzocyclooctyl (DBCO) and between 2.2–3.6 ppm indicating

the hydrogens of the azide apart from the peaks for the sulfonamides between 7.8–8.0 ppm.

2

.2. Drug Loading

The process of drug loading was performed at room temperature as described in the synthesis

in Section 4.1. The extent of drug loading was computed utilizing High performance liquid

chromatography (HPLC) and UV Spectrophotometry at 227 nm for absorbance of PTX. The

concentration of drug loaded was computed by utilizing a standard graph previously established.

The drug loading was observed to be around 11.3% w/w for PTX in this hypoxia-targeting drug

delivery system.

2

.3. Particle Size Analysis

The investigations for measurement of the particle size of the formulation of this study were

performed by the Dynamic light scattering (DLS) and Transmission electron microscopy (TEM).

The outcomes demonstrated that the particle size (Figure 1a) on average was 294.0 nm and the

polydispersity index (PDI) was around 0.139 demonstrating that the vast majority of the particles

were inside the scope of this normal size. Further, the molecule size and morphology were considered

utilizing TEM which indicated particles (Figure 1b) of the size between 105 and 130 nm. Both these

outcomes afﬁrm that the particle size is within the nanoscale.

Figure 1.

(a) Particle size by Dynamic light scattering (DLS) of the hypoxia targeting drug delivery

system HSA-PTX-ATZ; (

b) Particle size and morphology by Transmission electron microscopy (TEM)

of the hypoxia targeting drug delivery system HSA-PTX-ATZ.

2

.4. Drug Release Studies

Drug release studies were carried out as described in Section 4.4. The drug release studies were

carried out at the physiological pH of 7 because it corresponds to that of the blood. The drug released

after the albumin nanoparticles were broken down was calculated using both UV and HPLC and the

results were consistent. The release was found to be steady over a period of 72 h with a release of

about 29.75% at 24 h and 42.62% at 72 h (Figure 2). This shows that the product under study can be

considered as a sustained release formulation.

Figure 2. Drug release studies at pH 7 for the hypoxia targeting drug delivery system HSA-PTX-ATZ.

Int. J. Mol. Sci. 2018, 19, 838

5 of 21

2

.5. Stability Studies

Stability studies are preformed to test the resistance of the formulation to drug loss over a period

of time and to the aggregation of nanoparticles. Thus, these studies have been done in three aspects of

particle size, PDI and the drug loss over a period of 12 weeks or three months and the results are shown

in Figure 3. As can be seen, the particle size seems to very slightly ﬂuctuate but after a slight amount

of agitation, the particle size seemed to be more or less the same; 292.5 nm at room temperature. The

particle size was found to be more stable when frozen over that time than at the other two conditions.

Similarly, there have been ﬂuctuations in the PDI and at the end of the 12 weeks it was around 0.136.

As for the drug loss, the loss was at 3.0% at room temperature after 12 weeks but was lesser in the

frozen conditions which was of the order of 1.4%.

Figure 3. Stability studies over a period of 12 weeks for the hypoxia targeting drug delivery system

HSA-PTX-ATZ. * Statistically not signiﬁcant.

2

.6. In Vitro Cytotoxicity Studies

These studies were performed on two different cell lines each expressing the CA IX receptor to a

different extent [111

shown that the MDA-MB-231 shows an IC₅₀at around 1

m in the MDA-MB-468 cell line as calculated via graphical and mathematical calculations from both

,

112]. In this direction, the results (Figure 4) of the in vitro cytotoxicity studies have

µm of the drug in the formulation as well as

1

µ

MS Excel and GraphPad Prism 7. The results showed a dose-dependent killing and also a cell viability

much lower than the non-targeted preparation and free drug in both cell lines at each concentration.

The higher viability of the cells of the order of 80–90% for the carrier ligand combination additionally

shows that the carrier along with ligand are safe for use. Statistical analysis was performed to calculate

the signiﬁcance of difference between free PTX and HAS-PTX-ATZ formulation in the two cell lines.

Int. J. Mol. Sci. 2018, 19, 838

6 of 21

Figure 4. In vitro cytotoxicity studies in MDA-MB-231 and MDA-MB-468 cell lines respectively for the

hypoxia targeting drug delivery system HSA-PTX-ATZ. ** Statistically signiﬁcant.

2

.7. Comparative In Vitro Cytotoxicity Studies for Normoxic and Hypoxic Conditions

This test proves that the presence of the ligand results in a higher uptake of the formulation in the

hypoxic conditions and also that the CA IX receptor expression in normoxic conditions is much lower

than the hypoxic conditions which results in the difference in uptake of the formulation in hypoxic

conditions. The hypoxic condition was induced by the use of CoCl₂[118,119]. The normoxic condition

was achieved by the absence of treatment of the cells with CoCl . This was carried out at the IC₅₀

2

concentration for the formulation in both cell lines calculated from the in vitro cytotoxicity studies.

The results from Figure 5 show that the cytotoxicity of the formulation in the hypoxic conditions

is much less than in the hypoxic conditions with the values of the cell viability being about 92% in

normoxic conditions and around 51% in the hypoxic condition in both cell lines. This also proves that

the formulation is quite safe in normal cells.

Figure 5. Comparative in vitro cytotoxicity studies for normoxic and hypoxic conditions in

MDA-MB-231 and MDA-MB-468 cell lines respectively for the hypoxia targeting drug delivery system

HSA-PTX-ATZ. ** Statistically signiﬁcant.

2

.8. Fluorescence Spectroscopic Studies

The ﬂuorescence spectroscopic assay determines quantitatively the amount of drug entering the

cells. The conjugation of rhodamine B to the drug and the nanomicelles and its subsequent detection

in the spectrometer is time- and drug-concentration-dependent. The more rhodamine concentration

detected with time means the more of the formulation along with the encapsulated drug might be

entering the cells. The results of this assay show that the uptake of the formulation in the cells of both

the cell lines increases with time taken at the time intervals of 4, 8, 16 h (Figure 6). The results have been

presented in terms of ﬂuorescence emission intensity as well as the concentration of rhodamine B that

Int. J. Mol. Sci. 2018, 19, 838

7 of 21

is conjugated to the formulation. The graph also depicts that the uptake of the targeted formulation in

both the cell lines is more than the non-targeted formulation.

Figure 6. Fluorescence spectroscopic studies in MDA-MB-231 and MDA-MB-468 cell lines respectively

for the hypoxia targeting drug delivery system HSA-PTX-ATZ. ** Statistically signiﬁcant.

2

.9. Apoptosis Assay by Flow Cytometry

Apoptosis is induced in both the cell lines because of the treatment with the formulations as was

analyzed by ﬂow cytometry with Annexin V/7-AAD dual staining [20

V+/7-AAD+ (R3), Annexin V /7-AAD+ (R4), Annexin V /7-AAD (R5), and Annexin V+/7-AAD

R6) were utilized to illustrate the percentage of live cells, early apoptotic, late apoptotic and necrotic

,120]. The levels of Annexin

−

(

cells. The percentage of apoptotic cells was observed to be signiﬁcantly higher in both the cell lines

treated with the targeted formulation when compared to free drug non-targeted formulations. The

percentage of early and late apoptotic cells in the MDA-MB-231 cell line was observed to be around

5

0.7% and 23.5%, respectively, in targeted formulation treated cells and 42.9% and 3.4%, respectively,

in the non-targeted formulation-treated cells (Figure 7a). The percentage of early and late apoptotic

cells in MDA-MB-468 cells was observed to be around 39.3% and 35.2%, respectively, in targeted

formulation treated cells and 45.9% and 3.3%, respectively, in the non-targeted formulation-treated cells

(

Figure 7b). The outcomes present a superior apoptosis-inducing capacity of the targeted formulation.

The graphical representation of these results has been demonstrated in Figure 8a,b. These results

were consistent with cytotoxicity studies, cell uptake studies and the confocal microscopic studies.

Additionally, the blank formulation displayed generally low apoptosis in the cell line, demonstrating

the safety of the carrier system when utilized for treatment.

Figure 7. Apoptosis assay studies in (a) MDA-MB-231 and (b) MDA-MB-468 for the hypoxia targeting

drug delivery system HSA-PTX-ATZ (The results are presented in terms of percentage of apoptotic

cells similar to the previous literature [5,6,23,24,28,121]).

Int. J. Mol. Sci. 2018, 19, 838

8 of 21

Figure 8. (a) Graphical representation of the apoptosis assay studies in MDA-MB-231; (b) Graphical

representation of the apoptosis assay studies in MDA-MB-468 for the hypoxia targeting drug delivery

system HSA-PTX-ATZ.

3

. Discussion

It is the objective of each targeted drug delivery system to develop a framework for the

nano-delivery formulations to address the difﬁculties discussed so far by building up a reagent-free

click chemistry process. There have been a few studies conducted and strategies created to set

up such click chemical reactions as of late that are anything but difﬁcult to be performed, are

brisk and yield high amounts of these products with non-poisonous results. A few analysts

now consider that click chemistry is a carefully engineered approach towards the development

of new molecular delivery systems. This unique yet simple technique depends basically upon

the development of carbon heteroatom bonds utilizing spring-loaded reactants. The increasing

extent of utilization of these reactions in delivery systems is found in about all specializations

of current pharmaceutical sciences from drug delivery to material sciences [121]. These sorts of

click chemistry reactions extensively incorporate cycloaddition of unsaturated species: 1,3-dipolar

cycloaddition, cycloaddition of unsaturated species: [4+2]-cycloaddition (Diels-Alder), nucleophilic

substitution/ring-opening responses, carbonyl responses of the non-aldol sort, expansion to

carbon-carbon numerous securities [122]. Because of the undeniable favorable circumstances of

such simple chemical reactions, the click chemistry has been picking up in drug discovery, drug

delivery, and bioconjugation reactions [40]. Its application is utilized as a strategy for creating libraries

of such targeted drug delivery systems.

The formulation thus synthesized is a result of such a simple chemical process involving three

steps only, thus creating a feasibility of formulating such delivery systems for a combination of

ligands and carriers for several hydrophobic drugs of different categories and not just limited to the

anti-cancer drugs. The safety of the carrier system thus developed is the key for the success of this

formulation. Both the targeted and non-targeted formulations were prepared so that they can be

compared to each other for their anti-cancer efﬁciency. The drug loading is suspected to be less in

the formulation due to the long duration of the reaction and due to the size of the carrier molecule.

However, the same spatial reasons can be given for the prolonged and sustained release of the drug

into the tumor microenvironment.

The nanoparticles thus formed are found to be in the nanoscale of the particle size and the TEM

results further conﬁrm these results. The PDI was found to be quite low indicating that the size

distribution is quite narrow in the particles which means that most of the nanoparticles were about the

same size as the average particle size. The particles being in the nano size also promote the entry of the

Int. J. Mol. Sci. 2018, 19, 838

9 of 21

formulation into the tumor cells through the leaky vasculature by the EPR effect [61

,88]. Furthermore,

the particle size below 300 nm also helps prevent opsonization of the proteins via macrophages in the

body that untimely leads to elimination of the formulation from the targeted tumor site. The results of

the DLS and TEM are corroborative and form the basis for the results of the cytotoxicity studies.

The formulation further tested for the stability shows that the nature of the formulation is

maintained close to the nature at the point of its synthesis. Thus, the formulation is found to be robust

with little drug loss. This is an indication towards the long shelf-life possible by this formulation

strategy. The storage conditions may also well be described from the results of this study as being

stored at freezing temperatures for the longest shelf-life with the best possible stability and minimal

drug loss during storage.

The cytotoxic studies were then performed to check the efﬁciency of the formulation in vitro

The formulation was found to have a little bit more efﬁcacy in the MDA-MB-468 cell lines which have

an overexpression of the extracellular CA IX receptor under hypoxic conditions and, hence, show

good response to treatment. This effect is more or less the same in MDA-MB-231 cells [123]. Hence,

the formulation does show a reasonable efﬁciency in this cell line also showing that it is a promising

strategy to treat this more aggressive cell line [124]. Hence, based on the literature [124], we established

a proof of concept that this formulation is effective in hypoxic conditions equally in both cell lines.

The hypoxic conditions are found to have more of an effect because of the lowering of the pH in

the swiftly proliferating cancer cells that results in the overexpression of this receptor and, thus, the

formulation being taken up more effectively. The difference in cell viability between the targeted

and non-targeted formulations is an indication of the fact that the formulation is being taken up not

only by EPR effect but also by the targeted entry via the extracellular CA IX receptor; i.e., receptor

mediated cell uptake [14]. The high cell viability in the blank formulation is proof of the safety of the

carrier-ligand system. Furthermore, the difference in the response to this formulation in the normoxic

.

(higher cell viability) and hypoxic conditions (lower cell viability) has led us to demonstrate that the

uptake mechanism was CA IX receptor-mediated in TNBC cells. These studies establish the proof of

concept of concept to show that this formulation is an efﬁcient way to deliver drugs via targeting the

hypoxia marker, CA IX.

The in vitro cytotoxicity studies were followed up by ﬂuorescence spectroscopic studies

that illustrated the extent of uptake of the formulation in the cells. The comparative results

between the non-targeted and targeted formulations show that the targeted formulation has

a more preferential uptake in hypoxic conditions and the results show that the uptake is

time-dependent. Thus, it corroborates the results of the cytotoxicity studies showing receptor-mediated

uptake [13,31,106,125–127] of the formulation in addition to the EPR effect. The uptake of the

non-targeted formulation may be explained as being purely a response to the EPR effect. Acetazolamide

is a very established ligand of CA IX [112,128–133]. Our data of high cell killing effects of

HSA-PTX-ATZ in hypoxic condition compared to normoxia and higher uptake of Rhodamine-labelled

HSA-PTX-ATZ indicate the CA IX-mediated drug delivery effect of HSA-PTX-ATZ.

The ﬁndings of the cytotoxic studies and the ﬂuorescence spectroscopic studies are further

strengthened by the percentage of early and late apoptotic cells in both cell lines. The higher percentage

of apoptotic cells proves the efﬁciency of the targeted formulation in both cell lines; this demonstrates

the advantage of the targeting ligand. The low percentage of total apoptotic cells in the cell with the

carrier system shows that the system is safe for normal cells.

4

. Materials and Methods

4

.1. Synthesis of the Hypoxia Targeting Drug Delivery System

The synthesis of the drug delivery system developed in this study that targets hypoxia in the

tumor cells is a simple four step utilizing click chemistry. As mentioned earlier, click chemistry is a

quick process of conjugating two molecules that have complimentary functional groups that just ‘click’

Int. J. Mol. Sci. 2018, 19, 838

10 of 21

with each other in minimal conditions of the reaction. The speciﬁc form of click reaction used in this

study is the copper free cyclic Alkyne-Azide click reaction. The convenience of this reaction process

allows the development of a library of ligands and carrier molecules that have these complimentary

molecules which can take part in click reaction that can be made on a need-basis. The scheme of this

reaction is presented in the Figure 9.

Figure 9. Schematic representation of the synthesis of the hypoxia targeting drug delivery

system HSA-PTX-ATZ.

Int. J. Mol. Sci. 2018, 19, 838

11 of 21

The description of this process is as follows:

4

.1.1. Preparation of the Targeting Ligand

The ﬁrst step is to prepare the ligand on the HSA molecule. The starting material is the

Acetazolamide. The amide group of the acetazolamide is ﬁrst converted to primary amine by acid

hydrolysis using 1 M HCl. The primary amine group thus activated is then used to be attached to one

of the complimentary molecule, DBCO with a —-C≡≡C—- group that further participates in the click

reaction. The acetazolamide with the primary amine group and the DBCO are dissolved in DMSO and

then allowed to react for overnight at room temperature while stirring continuously. The product is

then dialyzed in a 12 kD dialysis bag (Spectrapor, Spectrum Research facilities, SD) for 4–8 h and kept

ready for further conjugation.

4

.1.2. Preparation of the Carrier Molecule

Preparation of the carrier molecule is the next step. This involves conversion of the amine group of

the amino acids comprised in the HSA protein to azide group. This involves two steps. First, the amine

−

+

−

groups are converted to azide groups, N== N== N , using the Stick Reagent (imidazole-1-sulfonyl

azide) in the presence of K CO overnight at room temperature and continuous stirring. The addition

2

3

of these two components of the reaction is carried out in ice because they are highly exothermic

reactions. After the conversion, the azide product is dialyzed in a 12 kD dialysis bag (Spectrapor,

Spectrum Research facilities, SD) for 4–8 h and the drug is loaded onto it.

4

.1.3. Drug Loading on the Carrier Molecule Comprising the Azide Group

The drug loading is performed by desolvation method that is derived from the coacervation

process using previously described method in the literature [28,69,134,135]. Paclitaxel is a hydrophobic

drug that is dissolved in ethanol. HSA was at ﬁrst completely dissolved in phosphate buffer made

in deionized water (50 mg/mL) and placed on a stirrer at a speed of around 600 rpm. The pH of

the buffer is maintained at 8. The ethanolic solution of the PTX is then added to the HSA solution

at the rate of 1 mL/min. The pH is again maintained at 8 using the same buffer. After half an hour

of stirring, 8% glutaraldehyde is added to the reaction mixture to promote crosslinking in the HSA

for encapsulating the drug effectively. The reaction is continued overnight while stirring at room

temperature. The product is then dialyzed in a 12 kD dialysis bag (Spectrapor, Spectrum Research

facilities, SD) for 4–8 h. This drug loaded carrier molecule with the azide group contributes the other

complimentary molecule of the click reaction.

4

.1.4. Conjugation of the Ligand to the Carrier Molecule

This is the ﬁnal step of the process of synthesis of the hypoxia targeting drug delivery system.

It involves the conjugation of the alkyne group on DBCO and the azide group on the carrier molecule

click conjugate with each other. This is the simplest step of the process where in the ligand containing

the DBCO and the carrier molecule with the azide are combined together in a reaction under pH

condition of 8 and at room temperature while continuously stirring at 600 rpm. The reaction is carried

out for 4–6 h. The ﬁnal product is dialyzed in a 12 kD dialysis bag (Spectrapor, Spectrum Research

facilities, SD) for 2 h and lyophilized. The ﬁnal product is water soluble. The product can also be

attached further with an NIR dye by the similar click reaction to produce a theranostic product. This is

further taken up for characterization studies using FTIR and NMR studies to conﬁrm the reaction.

4

.2. Drug Loading

The process of drug loading was performed at room temperature as described earlier in the

synthesis section. The calculation of percentage of drug loading was performed in HPLC and UV

Spectrophotometer and the amount of drug encapsulated was found out using the standard graph

Int. J. Mol. Sci. 2018, 19, 838

12 of 21

previously developed by the methods speciﬁed in literature for PTX in both the HPLC and UV

Spectrophotometer. A series of dilutions were made for the pure PTX and the absorbance for each was

taken at 227 nm. A standard graph was plotted according to the readings. Later, a speciﬁed amount of

the product has been taken and tested for absorbance. The amount of drug encapsulated from the line

equation obtained from the standard graph.

4

.3. Particle Size Analysis

The nanoparticles were further taken for particle size studies using a Beckman Coulter Delsa

Nano-C DLS Particle analyzer (Beckman Coulter, Inc., Fullerton, CA, USA) that involved a 658 nm

He–Ne laser as reported earlier by our lab. Tests were also examined by JEOL Transmission Electron

Magnifying Instrument outﬁtted with LaB6 ﬁlament gun (JEM 2010, Tokyo, Japan) at an accelerating

voltage of 200 kV for studying the particle morphology [

for surface morphology by Transmission Electron Microscopy (TEM). Tests were set up as described in

the previous literature. Determined measure of each sample (4 L) was applied to a Formvar-coated,

carbon stabilized copper matrix (400 work). The copper matrix was air-dried, stained negatively with

6,8,53]. The nanoparticles were also depicted

µ

5

% aqueous uranyl acetate, and allowed to dry.

4

.4. Drug Release Studies

Drug release studies were performed with the formulation to assess the extent to which the

drug has been released out from the formulation. Ideally, this is done in the physiological conditions.

For this study, the studies were carried out at pH 7. The analysis was carried out at room temperature.

A ﬁxed volume of the formulation was placed in a dialysis bag under sink condition and continuous

stirring. Speciﬁc volumes of samples were extracted at 2, 4, 8, 10, 12, 24, 48, 72 h from the dialysis

bag. The nanoparticles were subjected to high shear in a sonicator for about 15–30 min to disrupt the

nanoparticle formation so that the entire drug is released out and then the mixture was centrifuged at

high speed of 15,000 rpm for 15 min. This forms a pellet of the disrupted HSA (being a heavy molecule

in comparison to the drug) at the bottom and the supernatant contains the drug. The supernatant

was extracted, diluted and then analyzed for drug content in UV and HPLC. The amount of was

calculated from the line equation obtained from the standard graph and subtracted from the amount

in the sample ﬁrst taken to get the amount of drug released.

4

.5. Stability Studies

The stability studies were performed to check for the stability of the formulation over a period of

time in terms of particle size, polydispersity index (PDI), and drug loss. The formulation prepared

◦

was stored at three different conditions of temperatures, i.e., at room temperature (25 C), under

◦

refrigeration (4 C), and under frozen conditions ( 20 C) for 12 weeks [5,98]. The samples were

retrieved every week and analyzed for the particle size, and PDI in DLS and drug content was analyzed

in HPLC and UV.

−

4

.6. Cell Culture

The cell lines chosen for this study are the MDA-MB-231 and MDA-MB-468 both of which

correspond to the Triple Negative Breast Cancer (TNBC) [136 137]. These were the choice of cell lines

,

because they are known to express the hypoxia marker Carbonic Anhydrase IX (CA IX) receptor on the

surface of the cell lines. The MDA-MB-468 is found have a higher expression of the receptor compared

to the MDA-MB-231 according to literature. The MDA-MB-231 is also found to be a more aggressive

cell line that presents a greater difﬁculty for treatment. MDA-MB-231 is a stellate shaped cell and the

MDA-MB-468 is a grape-like cluster of cells. Both the cell lines were cultured in Dulbecco’s Modiﬁed

Eagle’s Medium (DMEM; Fisher Scientiﬁc, Waltham, MA, USA). The media was added with 10% fetal

◦

bovine serum (FBS) and streptomycin sulfate (10 mg/L). All cell lines were incubated at 37 C in a 5%

CO air humidiﬁed atmosphere.

2

Int. J. Mol. Sci. 2018, 19, 838

13 of 21

4

.7. In Vitro Cytotoxicity Studies

The in vitro cytotoxicity studies were performed after the cells were induced with hypoxia using

CoCl . This treatment enhances the overexpression of the CA IX receptor on the surface of the cells.

2

The assay was performed using the MTT reagent solution in PBS (1 mg/mL) at pH 7.4. The treatments

included free drug (positive control), free carrier (negative control), carrier-drug (positive control),

carrier-ligand (negative control), and the formulation comprising carrier-ligand-drug. The cells were

seeded in 96-well plates with a normal of 5000 cells in each well. After incubating these cells for

2

4 h, they were treated with different concentrations of the formulations within a range of 0.25–5

µ

m.

◦

The treated cells were further incubated in the presence of the formulations for 48 h at 37 C, after

which the MTT reagent solution was added. The cells were incubated furthermore at 37 C for

◦

2

h. Following this, the media was supplanted by DMSO and the plates were put on a shaker for

10 min. The absorbance was measured at 590 nm utilizing a high-performance multi-mode plate

reader (Synergy 2, BioTek, Winooski, VT, USA). The extent of surviving cells was calculated in terms

of percentage by contrasting the absorbance of the treated cells and proper controls cells. This was

performed on both the cell lines individually. Statistical analysis was done to calculate the signiﬁcance

of difference between the responses to the formulation in both cell lines.

4

.8. Comparative In Vitro Cytotoxicity Studies for Normoxic and Hypoxic Conditions

Healthy cells and cancer cells show a difference in terms of development of hypoxia and acidic

conditions in the microenvironment. The healthy cells do not overexpress the CA IX receptor and

do not exhibit hypoxia while the cancer cells do. Thus, this study was performed to understand

the difference in the uptake of speciﬁcally the formulation in the normoxic conditions as well as the

hypoxic conditions in the said cell lines. This study is believed to give an assessment of the effect

of the formulation on the normal and the tumor cells. The study was done similar to the in vitro

cytotoxicity studies described above in two groups of treatments; the cells that are treated with CoCl₂

to induce hypoxia and CA IX expression and the cells that are not treated with CoCl for normoxia.

2

The assay was performed using MTT reagent solution (1 mg/mL) in both the cell lines. The assay

was performed at the IC₅₀concentration of speciﬁcally the formulation to prove its efﬁciency in the

hypoxic conditions comparatively.

4

.9. Fluorescence Spectroscopic Studies

This assay is a quantitative measure of the amount of formulation encapsulating the drug entering

into the cells using ﬂuorescence spectroscopy. Both the targeted and non-targeted formulations

were conjugated with Rhodamine B according to a previously established method. The cell-lines

MDA-MB-231 and MDA-MB-468 were treated with CoCl ﬁrst, then cultured in two separate 6

2

well-plates with each well comprising of about 100,000 cells in 2 mL of the media. These cells were

then treated with the rhodamine conjugated formulations at their IC₅₀concentrations and incubated.

Samples were collected every 4 h from the start of the treatment. Each sample collection procedure

consisted of removing the formulation, washing it with PBS, and ﬁnally streaking the cells to collect the

proteins and then further protein collection using lysis buffer. During the measurement of ﬂorescence,

a control was also used that contained a mixture of methanol and the lysis buffer.

4

.10. Apoptosis Assay by Flow Cytometry

Apoptosis assay was performed on the MDA-MB-231 and MDA-MB-468 cell lines separately

according to the prior literature. The cells were induced with hypoxia by treating them with CoCl₂,

then the cells were cultured in 6-well plates at the rate of 100,000 cells per well. The cells were

◦

incubated for 24 h at 37 C under 5% CO , followed by the treatment of the cells with free drug,

2

non-targeted formulation and the targeted formulation and incubating further for 48 h to induce

apoptosis. The concentrations of the formulations were the IC₅₀concentrations of the respective

Int. J. Mol. Sci. 2018, 19, 838

14 of 21

formulations obtained from the in vitro cytotoxicity assay. After a 48-h incubation, the cells were

gathered, and the test was set up as indicated by the procedure described for Guava Nexin Annexin

V assay (EMD Millipore, Billerica, MA, USA). Then, the media before trypsinization and the treated

trypsinized cells were gathered in 15 mL tubes for each sample and centrifuged at 800 for 5 min. Cell

pellets formed thus were dispersed in PBS at pH 7.4 containing 1% FBS so that the quantity of cells of

5

6

the order of 2

with 100 L of the Guava Nexin Reagent and was incubated for 20 min at room temperature in the

absence of sunlight. The resultant ﬁnal samples were analyzed by Guava Easycyte Flow Cytometer

EMD Millipore).

×

10 to 1

×

10 cells/mL. 100 µL of these cell dispersions of each sample was mixed

µ

(

5

. Conclusions

Hypoxia is a target that is ubiquitously present in almost all cancers and is mostly found in the

oxygen-deprived core of the tumor. It is a challenge to target it because of its location. However, the

fast-growing cancer cells produce a lack of oxygen and a lowering of pH in the cancer cells which

result in the overexpression of the surface receptor CA IX. This is a convenient cancer cell marker that

allows the penetration of the nanocarrier to the core and, thus, effectively delivers the drug to the

targeted site. This study is an attempt to establish the proof-of-concept that this can be achieved via

the use of CA IX-targeting ligands like Acetazolamide and a bio-safe carrier like the human serum

albumin which is abundant in the body and, hence, is non-immunogenic. This study succeeded in

proving the usefulness of the formulation synthesized herein and characterized further. It shows that

the cells selectively take up the formulation and shows a low cell viability in cancer cells with more

percentage of apoptotic or dying cells. The results also show that the carrier system is safe and hence

can be used for drug delivery. The delivery system, therefore, helps in the delivery of drugs to speciﬁc

sites; thus, eliminating the undesired side effects on healthy cells. The nature of the formulation further

allows the conjugation of a dye that can potentially make it a theranostic system. Thus, it can be safely

said that the formulation can be further used for in vivo evaluations that are currently underway in

our laboratory.

Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/3/

8

38/s1 .

Acknowledgments: Katyayani Tatiparti would like to acknowledge AGRADE scholarship from the Wayne State

University Graduate School to pursue PhD Studies in Iyer Lab, Department of Pharmaceutical Sciences, Wayne

State University (WSU). The authors wish to acknowledge the funding support from US National Institutes of

Health, National Cancer Institute (NIH/NCI) grant R21CA179652 and Wayne State University Start-up funding

to Arun K. Iyer.

Author Contributions: The research was performed by the efforts of Katyayani Tatiparti with equal intellectual

contributions from Samaresh Sau. Kaustubh A. Gawde has provided help in performing some of the key

experiments. Arun K. Iyer has supervised the research entirely as the Principal Investigator.

Conﬂicts of Interest: The authors have no afﬁliations with or involvement in any organization or entity with any

ﬁnancial interest or non-ﬁnancial interest in the subject matter or materials discussed in this manuscript.

References

1

.

CDC Expected New Cancer Cases and Deaths in 2020; Centers for Disease Control and Prevention: Atlanta, GA,

USA, 2015.

2

.

Sau, S.; Alsaab, H.O.; Bhise, K.; Alzhrani, R.; Nabil, G.; Iyer, A.K. Multifunctional nanoparticles for cancer

immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.

J. Control. Release 2018. [CrossRef ] [PubMed ]

3

.

Yang, X.; Iyer, A.K.; Singh, A.; Milane, L.; Choy, E.; Hornicek, F.J.; Amiji, M.M.; Duan, Z. Cluster of

differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug

resistance in ovarian cancer. Pharm. Res. 2015, 32. [CrossRef ] [PubMed ]

Int. J. Mol. Sci. 2018, 19, 838

15 of 21

4

5

6

7

8

.

Wickens, J.M.; Alsaab, H.O.; Kesharwani, P.; Bhise, K.; Amin, M.C.I.M.; Tekade, R.K.; Gupta, U.; Iyer, A.K.

Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy. Drug Discov. Today

017, 22. [CrossRef ] [PubMed ]

Luong, D.; Sau, S.; Kesharwani, P.; Iyer, A.K. Polyvalent folate-dendrimer-coated iron oxide

theranostic nanoparticles for simultaneous magnetic resonance imaging and precise cancer cell targeting.

Biomacromolecules 2017, 18, 1197–1209. [CrossRef ] [PubMed ]

Luong, D.; Kesharwani, P.; Alsaab, H.O.; Sau, S.; Padhye, S.; Sarkar, F.H.; Iyer, A.K. Folic acid conjugated

polymeric micelles loaded with a curcumin diﬂuorinated analog for targeting cervical and ovarian cancers.

Colloids Surf. B Biointerfaces 2017, 157, 490–502. [CrossRef ] [PubMed ]

Kesharwani, P.; Xie, L.; Mao, G.; Padhye, S.; Iyer, A.K. Hyaluronic acid-conjugated polyamidoamine

dendrimers for targeted delivery of 3,4-diﬂuorobenzylidene curcumin to CD44 overexpressing pancreatic

cancer cells. Colloids Surf. B Biointerfaces 2015, 136, 413–423. [CrossRef ] [PubMed ]

Kesharwani, P.; Banerjee, S.; Padhye, S.; Sarkar, F.H.; Iyer, A.K. Hyaluronic acid engineered nanomicelles

loaded with 3,4-diﬂuorobenzylidene curcumin for tar geted killing of CD44+ stem-like pancreatic cancer

cells. Biomacromolecules 2015, 16, 3042–3053. [CrossRef ] [PubMed ]

Iyer, A.K.; Duan, Z.; Amiji, M.M. Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors.

Mol. Pharm. 2014, 11, 2511–2526. [CrossRef ] [PubMed ]

2

9

1

0. Ganesh, S.; Iyer, A.K.; Gattacceca, F.; Morrissey, D.V.; Amiji, M.M. In vivo biodistribution of siRNA and

cisplatin administer ed using CD44-targeted hyaluronic acid nanoparticles. J. Control. Release 2013, 172,

6

99–706. [CrossRef ] [PubMed ]

1

1. Ganesh, S.; Iyer, A.K.; Weiler, J.; Morrissey, D.V.; Amiji, M.M. Combination of siRNA-directed gene silencing

with cisplatin reverses drug resistance in human non-small cell lung cancer. Mol. Ther. Nucleic Acids 2013, 2.

[CrossRef ] [PubMed ]

2. Choudhury, H.; Gorain, B.; Pandey, M.; Kumbhar, S.A.; Tekade, R.K.; Iyer, A.K.; Kesharwani, P. Recent

advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy. Int. J. Pharm. 2017, 529.

[CrossRef ] [PubMed ]

3. Amjad, M.W.; Amin, M.C.I.M.; Katas, H.; Butt, A.M.; Kesharwani, P.; Iyer, A.K. In vivo antitumor activity

of folate-conjugated cholic acid-polyethylenimine micelles for the codeliv ery of doxorubicin and sirna to

colorectal adenocarcinomas. Mol. Pharm. 2015, 12, 4247–4258. [CrossRef ] [PubMed ]

1

4. Alsaab, H.; Alzhrani, R.; Kesharwani, P.; Sau, S.; Boddu, S.; Iyer, A. Folate decorated nanomicelles loaded with

a potent curcumin analogue for targeting retinoblastoma. Pharmaceutics 2017, 9, 15. [CrossRef ] [PubMed ]

5. Abeylath, S.C.; Ganta, S.; Iyer, A.K.; Amiji, M. Combinatorial-designed multifunctional polymeric

nanosystems for tumor-targeted therapeutic delivery. Acc. Chem. Res. 2011, 44, 1009–1017. [CrossRef ]

1

[PubMed ]

1

2

6. Cheriyan, V.T.; Alsaab, H.O.; Sekhar, S.; Stieber, C.; Kesharwani, P.; Sau, S.; Muthu, M.; Polin, L.A.; Levi, E.;

Iyer, A.K.; et al. A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for

inhibition of renal cell carcinoma. Oncotarget 2017, 8, 104928–104945. [CrossRef ] [PubMed ]

7. Almansour, A.I.; Arumugam, N.; Suresh Kumar, R.; Mahalingam, S.M.; Sau, S.; Bianchini, G.; Menéndez, J.C.;

Altaf, M.; Ghabbour, H.A. Design, synthesis and antiproliferative activity of decarbonyl luotonin analogues.

Eur. J. Med. Chem. 2017, 138, 932–941. [CrossRef ] [PubMed ]

8. Sau, S.; Agarwalla, P.; Mukherjee, S.; Bag, I.; Sreedhar, B.; Pal-Bhadra, M.; Patra, C.R.; Banerjee, R. Cancer

cell-selective promoter recognition accompanies antitumor effect by glucocorticoid receptor-targeted gold

nanoparticle. Nanoscale 2014, 6, 6745–6754. [CrossRef ] [PubMed ]

9. Susa, M.; Iyer, A.K.; Ryu, K.; Choy, E.; Hornicek, F.J.; Mankin, H.; Milane, L.; Amiji, M.M.; Duan, Z. Inhibition

of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in

osteosarcoma. PLoS ONE 2010, 5. [CrossRef ] [PubMed ]

0. Sau, S.; Mondal, S.K.; Kashaw, S.K.; Iyer, A.K.; Banerjee, R. Combination of cationic dexamethasone derivative

and STAT3 inhibitor (WP1066) for aggressive melanoma: A strategy for repurposing a phase I clinical trial

drug. Mol. Cell. Biochem. 2017, 436. [CrossRef ] [PubMed ]

2

1. Sahu, P.; Kashaw, S.K.; Kushwah, V.; Sau, S.; Jain, S.; Iyer, A.K. pH responsive biodegradable nanogels for

sustained release of bleomycin. Bioorg. Med. Chem. 2017, 25, 4595–4613. [CrossRef ] [PubMed ]

2. Sahu, P.; Das, D.; Kashaw, V.; Iyer, A.K.; Kashaw, S.K. Nanogels: A New Dawn in Antimicrobial Chemotherapy;

Elsevier: Amsterdam, The Netherlands, 2017; ISBN 9780323527347.

2

Int. J. Mol. Sci. 2018, 19, 838

16 of 21

2

3. Luong, D.; Kesharwani, P.; Killinger, B.A.; Moszczynska, A.; Sarkar, F.H.; Padhye, S.; Rishi, A.K.; Iyer, A.K.

Solubility enhancement and targeted delivery of a potent anticancer ﬂavonoid analogue to cancer cells using

ligand decorated dendrimer nano-architectures. J. Colloid Interface Sci. 2016, 484, 33–43. [CrossRef ] [PubMed ]

4. Luong, D.; Kesharwani, P.; Deshmukh, R.; Mohd Amin, M.C.I.; Gupta, U.; Greish, K.; Iyer, A.K. PEGylated

PAMAM dendrimers: Enhancing efﬁcacy and mitigating toxicity for effective anticancer drug and gene

delivery. Acta Biomater. 2016, 1–16. [CrossRef ] [PubMed ]

5. Khan, I.; Gothwal, A.; Sharma, A.K.; Kesharwani, P.; Gupta, L.; Iyer, A.K.; Gupta, U. PLGA nanoparticles

and their versatile role in anticancer drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 2016, 33. [CrossRef ]

[PubMed ]

6. Hadzijusufovic, E.; Rebuzzi, L.; Gleixner, K.V.; Ferenc, V.; Peter, B.; Kondo, R.; Gruze, A.; Kneidinger, M.;

Krauth, M.-T.; Mayerhofer, M.; et al. Targeting of heat-shock protein 32/heme oxygenase-1 in canine

mastocytoma cells is associated with reduced growth and induction of apoptosis. Exp. Hematol. 2008, 36,

1

467–1476. [CrossRef ] [PubMed ]

2

7. Gleixner, K.V.; Mayerhofer, M.; Vales, A.; Gruze, A.; Hörmann, G.; Cerny-Reiterer, S.; Lackner, E.;

Hadzijusufovic, E.; Herrmann, H.; Iyer, A.K.; et al. Targeting of Hsp32 in solid tumors and leukemias:

A novel approach to optimize anticancer therapy. Curr. Cancer Drug Targets 2009, 9. [CrossRef ]

2

8. Gawde, K.A.; Kesharwani, P.; Sau, S.; Sarkar, F.H.; Padhye, S.; Kashaw, S.K.; Iyer, A.K. Synthesis and

characterization of folate decorated albumin bio-conjugate nanoparticles loaded with a synthetic curcumin

diﬂuorinated analogue. J. Colloid Interface Sci. 2017, 496, 290–299. [CrossRef ] [PubMed ]

2

3

9. Ganesh, S.; Iyer, A.K.; Morrissey, D.V.; Amiji, M.M. Hyaluronic acid based self-assembling nanosystems for

CD44 target mediated siRNA delivery to solid tumors. Biomaterials 2013, 34, 3489–3502. [CrossRef ] [PubMed ]

0. Bhise, K.; Kashaw, S.K.; Sau, S.; Iyer, A.K. Nanostructured lipid carriers employing polyphenols as promising

anticancer agents: Quality by design (QbD) approach. Int. J. Pharm. 2017, 526, 506–515. [CrossRef ] [PubMed ]

1. Bhise, K.; Sau, S.; Alsaab, H.; Kashaw, S.K.; Tekade, R.K.; Iyer, A.K. Nanomedicine for cancer diagnosis and

therapy: Advancement, success and structure-activity relationship. Ther. Deliv. 2017, 8. [CrossRef ] [PubMed ]

2. Amiji, M.M.; Iyer, A.K. Multifunctional Self-Assembling Polymeric Nanosystems. United States Patent US

9

,173,840, 3 November 2015.

3. Jain, S.; Doshi, A.S.; Iyer, A.K.; Amiji, M.M. Multifunctional nanoparticles for targeting cancer and

inﬂammatory diseases. J. Drug Target. 2013, 21, 888–903. [CrossRef ] [PubMed ]

4. Agard, N.J.; Prescher, J.A.; Bertozzi, C.R. A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent

modiﬁcation of biomolecules in living systems. J. Am. Chem. Soc. 2004, 126, 15046–15047. [CrossRef ]

[PubMed ]

3

5. Baskin, J.M.; Prescher, J.A.; Laughlin, S.T.; Agard, N.J.; Chang, P.V.; Miller, I.A.; Lo, A.; Codelli, J.A.;

Bertozzi, C.R. Copper-fr ee click chemistry for dynamic in vivo imaging. Proc. Natl. Acad. Sci. USA 2007, 104,

1

6793–16797. [CrossRef ] [PubMed ]

3

4

6. Best, M.D. Click chemistry and bioorthogonal reactions: Unpr ecedented selectivity in the labeling of

biological molecules. Biochemistry 2009, 48, 6571–6584. [CrossRef ] [PubMed ]

7. Gundluru, M. Custom Synthesis of Strained Cyclooctyne-Peptide Conjugates for Copper-Free Click Chemistry;

Peptides International, Inc.: Louisville, KY, USA, 2018.

8. Jewett, J.C.; Bertozzi, C.R. Cu-free click cycloaddition reactions in chemical biology. Chem. Soc. Rev. 2010

9, 1272. [CrossRef ] [PubMed ]

,

3

9. Kolb, H.C.; Finn, M.G.; Sharpless, K.B. Click chemistry: Diverse chemical function from a few good reactions.

Angew. Chem. Int. Ed. 2001, 40, 2004–2021. [CrossRef ]

0. Kolb, H.C.; Sharpless, K.B. The growing impact of click chemistry on drug discovery. Drug Discov. Today

2

003, 8, 1128–1137. [CrossRef ]

1. Nandivada, H.; Jiang, X.; Lahann, J. Click chemistry: Versatility and control in the hands of materials

scientists. Adv. Mater. 2007, 19, 2197–2208. [CrossRef ]

2. Thirumurugan, P.; Matosiuk, D.; Jozwiak, K. Click chemistry for dr ug development and diverse

chemical-biology applications. Chem. Rev. 2013, 113, 4905–4979. [CrossRef ] [PubMed ]

3. Totobenazara, J.; Burke, A.J. New click-chemistry methods for 1,2,3-triazoles synthesis: Recent advances and

applications. Tetrahedron Lett. 2015, 56, 2853–2859. [CrossRef ]

Int. J. Mol. Sci. 2018, 19, 838

17 of 21

4

5

4. Sahu, P.; Kashaw, S.K.; Jain, S.; Sau, S.; Iyer, A.K. Assessment of penetration potential of pH responsive

double walled biodegradable nanogels coated with eucalyptus oil for the contr olled delivery of 5-ﬂuorouracil:

In vitro and ex vivo studies. J. Control. Release 2017, 253, 122–136. [CrossRef ] [PubMed ]

5. Iyer, A.K.; Su, Y.; Feng, J.; Lan, X.; Zhu, X.; Liu, Y.; Gao, D.; Seo, Y.; VanBrocklin, H.F.;

Courtney Broaddus, V.; et al. The effect of internalizing human single chain antibody fragment on liposome

targeting to epithelioid and sarcomatoid mesothelioma. Biomaterials 2011, 32. [CrossRef ] [PubMed ]

6. Jain, A.; Kesharwani, P.; Garg, N.K.; Jain, A.; Nirbhavane, P.; Dwivedi, N.; Banerjee, S.; Iyer, A.K.;

Mohd Amin, M.C.I. Nano-constructed carriers loaded with antioxidant: Boon for cardiovascular system.

Curr. Pharm. Des. 2015, 21, 4456–4464. [CrossRef ] [PubMed ]

7. Ng, K.E.; Amin, M.C.I.M.; Katas, H.; Amjad, M.W.; Butt, A.M.; Kesharwani, P.; Iyer, A.K. pH-responsive

triblock copolymeric micelles decorated with a cell-penetrating peptide provide efﬁcient doxorubicin delivery.

Nanoscale Res. Lett. 2016, 11. [CrossRef ] [PubMed ]

8. Mahor, A.; Prajapati, S.K.; Verma, A.; Gupta, R.; Iyer, A.K.; Kesharwani, P. Moxiﬂoxacin loaded gelatin

nanoparticles for ocular delivery: Formulation and in vitro, in vivo evaluation. J. Colloid Interface Sci.

2

016, 483. [CrossRef ] [PubMed ]

9. Daruwalla, J.; Greish, K.; Malcontenti-Wilson, C.; Muralidharan, V.; Iyer, A.; Maeda, H.; Christophi, C.

Styrene maleic acid-pirarubicin disrupts tumor microcirculati on and enhances the permeability of colorectal

liver metastases. J. Vasc. Res. 2009, 46, 218–228. [CrossRef ] [PubMed ]

0. Daruwalla, J.; Greish, K.; Nikfarjam, M.; Millar, I.; Malcontenti-Wilson, C.; Iyer, A.K.; Christophi, C.

Evaluation of the effect of SMA-pirarubicin micelles on color ectal cancer liver metastases and of hyperbaric

oxygen in CBA mice. J. Drug Target. 2007, 15. [CrossRef ] [PubMed ]

1. Susa, M.; Iyer, A.K.; Ryu, K.; Hornicek, F.J.; Mankin, H.; Amiji, M.M.; Duan, Z. Doxorubicin loaded

polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer

2

009, 9. [CrossRef ] [PubMed ]

2. Kobayashi, E.; Iyer, A.K.; Hornicek, F.J.; Amiji, M.M.; Duan, Z. Lipid-functionalized dextran nanosystems to

overcome multidrug resistance in cancer: A pilot study basic research. Clin. Orthop. Relat. Res. 2013, 471.

[CrossRef ] [PubMed ]

3. Kesharwani, P.; Banerjee, S.; Padhye, S.; Sarkar, F.H.; Iyer, A.K. Parenterally administrable nano-micelles

of 3,4-diﬂuorobenzylidene curcumin for treating pancreatic cancer. Colloids Surf. B Biointerfaces 2015, 132,

1

38–145. [CrossRef ] [PubMed ]

4. Amjad, M.W.; Kesharwani, P.; Mohd Amin, M.C.I.; Iyer, A.K. Recent advances in the design, development,

and targeting mechanisms of polymeric micelles for delivery of siRNA in cancer therapy. Prog. Polym. Sci.

2

017, 64, 154–181. [CrossRef ]

5

6

5. Iyer, A.K.; Singh, A.; Ganta, S.; Amiji, M.M. Role of integrated cancer nanomedicine in overcoming drug

resistance. Adv. Drug Deliv. Rev. 2013, 65, 1784–1802. [CrossRef ] [PubMed ]

6. Iyer, A.K.; He, J.; Amiji, M.M. Image-guided nanosystems for targeted delivery in cancer therapy. Curr. Med.

Chem. 2012, 19, 3230–3240. [CrossRef ] [PubMed ]

7. Singh, A.; Iyer, A.K.; Amiji, M.; Ganta, S. Multifunctional Nanosystems for Cancer Therapy; Elsevier: Amsterdam,

The Netherlands, 2013; ISBN 9780857096647.

8. Iyer, A.; Ganta, S.; Amiji, M. Polymeric Nanoparticles as Target-Speciﬁc Delivery Systems; Pan Stanford: Boca

Raton, FL, USA, 2010; ISBN 9789814267557.

9. Patel, R.; Patel, M.; Kwak, J.; Iyer, A.K.; Karpoormath, R.; Desai, S.; Rarh, V. Polymeric microspheres:

A delivery system for osteogenic differentiation. Polym. Adv. Technol. 2017, 28. [CrossRef ]

0. Zhang, L.; Iyer, A.K.; Yang, X.; Kobayashi, E.; Guo, Y.; Mankin, H.; Hornicek, F.J.; Amiji, M.M.;

Duan, Z. Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of

osteosarcoma cells. Int. J. Nanomed. 2015, 10, 2913–2924.

6

1. Iyer, A.K.; Greish, K.; Seki, T.; Okazaki, S.; Fang, J.; Takeshita, K.; Maeda, H. Polymeric micelles of zinc

protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J. Drug

Target. 2007, 15. [CrossRef ] [PubMed ]

2. Iyer, A.K.; Greish, K.; Fang, J.; Murakami, R.; Maeda, H. High-loading nanosized micelles of

copoly(styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor.

Biomaterials 2007, 28, 1871–1881. [CrossRef ] [PubMed ]

Int. J. Mol. Sci. 2018, 19, 838

18 of 21

6

3. Tatiparti, K.; Sau, S.; Kashaw, S.; Iyer, A. siRNA delivery strategies: A comprehensive review of recent

developments. Nanomaterials 2017, 7, 77. [CrossRef ] [PubMed ]

4. Kesharwani, P.; Iyer, A.K. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and

gene delivery. Drug Discov. Today 2015, 20, 536–547. [CrossRef ] [PubMed ]

5. Iyer, A.K.; Ave, M. Rational Design of Multifunctional Nanoparticles for Targeted Cancer Imaging and

Therapy. In Post-Genomic Approaches in Cancer and Nano Medicine; River Publishers: Gistrup, Denmark, 2016;

pp. 609–656.

6

6. Hyung, W.; Ko, H.; Park, J.; Lim, E.; Sung, B.P.; Park, Y.J.; Ho, G.Y.; Jin, S.S.; Haam, S.; Huh, Y.M. Novel

hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment. Biotechnol. Bioeng.

2

008, 99, 442–454. [CrossRef ] [PubMed ]

6

7. Huang, Y.; Mao, K.; Zhang, B.; Zhao, Y. Superparamagnetic iron oxide nanoparticles conjugated with folic

acid for dual target-speciﬁc drug delivery and MRI in cancer theranostics. Mater. Sci. Eng. C 2017, 70,

7

63–771. [CrossRef ] [PubMed ]

6

8. Ganapathy, V.; Moghe, P.V.; Roth, C.M. Targeting tumor metast ases: Drug delivery mechanisms and

technologies. J. Control. Release 2015, 219, 215–223. [CrossRef ] [PubMed ]

9. Feng, S.S.; Mei, L.; Anitha, P.; Gan, C.W.; Zhou, W. Poly(lactide)-vitamin E derivative/montmorillonite

nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials 2009, 30, 3297–3306. [CrossRef ]

[PubMed ]

7

0. Cui, M.; Naczynski, D.; Zevon, M.; Grifﬁth, C.K.; Sheihet, L.; Poventud-Fuentes, I.; Chen, S.; Roth, C.M.;

Moghe, P.V. Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral

chemotherapy. Adv. Healthc. Mater. 2013, 2, 1236–1245. [CrossRef ] [PubMed ]

1. Basak, S.K.; Zinabadi, A.; Wu, A.W.; Venkatesan, N.; Duarte, V.M.; Kang, J.J.; Dalgard, C.L.; Srivastava, M.;

Sarkar, F.H.; Wang, M.B.; et al. Liposome encapsulated curcumin-diﬂuorinated (CDF) inhibits the growth of

cisplatin resistant head and neck cancer stem cells. Oncotarget 2015, 6, 18504–18517. [CrossRef ] [PubMed ]

2. Kanapathipillai, M.; Brock, A.; Ingber, D.E. Nanoparticle targeting of anti-cancer drugs that alter intracellular

signaling or inﬂuence the tumor microenvironment. Adv. Drug Deliv. Rev. 2014, 79, 107–118. [CrossRef ]

[PubMed ]

3. Kim, T.H.; Jiang, H.H.; Youn, Y.S.; Park, C.W.; Tak, K.K.; Lee, S.; Kim, H.; Jon, S.; Chen, X.; Lee, K.C.

Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved

antitumor activity. Int. J. Pharm. 2011, 403, 285–291. [CrossRef ] [PubMed ]

4. Kim, W.; Thévenot, J.; Ibarboure, E.; Lecommandoux, S.; Chaikof, E.L. Self-assembly of thermally responsive

amphiphilic diblock copolypeptides into spherical micellar nanoparticles. Angew. Chem. Int. Ed. 2010, 49,

4

257–4260. [CrossRef ] [PubMed ]

5. Koide, H.; Yoshimatsu, K.; Hoshino, Y.; Lee, S.H.; Okajima, A.; Ariizumi, S.; Narita, Y.; Yonamine, Y.;

Weisman, A.C.; Nishimura, Y.; et al. A polymer nanoparticle with engineer ed afﬁnity for a vascular

endothelial growth factor (VEGF165). Nat. Chem. 2017, 9, 715–722. [CrossRef ] [PubMed ]

6. Makadia, H.K.; Siegel, S.J. Poly lactic-co -glycolic acid (PLGA) as biodegradable controlled drug delivery

carrier. Polymers 2011, 3, 1377–1397. [CrossRef ] [PubMed ]

7

7. Mohammadi, M.; Ramezani, M.; Abnous, K.; Alibolandi, M. Biocompatible polymersomes-based cancer

theranostics: Towards multifunctional nanomedicine. Int. J. Pharm. 2017, 519, 287–303. [CrossRef ] [PubMed ]

8. Padhye, S.; Banerjee, S.; Chavan, D.; Pandye, S.; Swamy, K.V.; Ali, S.; Li, J.; Dou, Q.P.; Sarkar, F.H.

Fluorocurcumins as cyclooxygenase-2 inhibitor: Molecular docking, pharmacokinetics and tissue distribution

in mice. Pharm. Res. 2009, 26, 2438–2445. [CrossRef ] [PubMed ]

7

8

9. Roy, E.; Patra, S.; Madhuri, R.; Sharma, P.K. Stimuli-responsive poly (N-isopropyl acrylamide)-co-tyrosine@

gadolinium: Iron oxide nanoparticle-based nanotheranostic for cancer diagnosis and treatment. Colloids Surf.

B Biointerfaces 2016, 142, 248–258. [CrossRef ] [PubMed ]

0. Song, Z.; Feng, R.; Sun, M.; Guo, C.; Gao, Y.; Li, L.; Zhai, G. Curcumin-loaded PLGA-PEG-PLGA triblock

copolymeric micelles: Pr eparation, pharmacokinetics and distribution in vivo. J. Colloid Interface Sci. 2011

,

3

54, 116–123. [CrossRef ] [PubMed ]

1. Wayua, C.; Roy, J.; Putt, K.S.; Low, P.S. Selective tumor targeting of desacetyl vinblastine hydrazide and

tubulysin b via conjugation to a cholecystokinin 2 receptor (CCK2R) ligand. Mol. Pharm. 2015, 12, 2477–2483.

[CrossRef ] [PubMed ]

Int. J. Mol. Sci. 2018, 19, 838

19 of 21

8

2. Maeda, H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues

related to its heterogeneity. Adv. Drug Deliv. Rev. 2015, 91, 3–6. [CrossRef ] [PubMed ]

3. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of

tumor-selective macromolecular drug targeting. Adv. Enzym. Regul. 2001, 41, 189–207. [CrossRef ]

4. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in

macromolecular therapeutics: A review. J. Control. Release 2000, 65, 271–284. [CrossRef ]

5. Nakamura, Y.; Mochida, A.; Choyke, P.L.; Kobayashi, H. Nanodrug delivery: Is the enhanced permeability

and retention effect sufﬁcient for curing cancer? Bioconjug. Chem. 2016, 27, 2225–2238. [CrossRef ] [PubMed ]

6. Greish, K. Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine:

Are we there yet? Drug Discov. Today Technol. 2012, 9, e161–e166. [CrossRef ] [PubMed ]

7. Maeda, H. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy.

Adv. Drug Deliv. Rev. 2001, 46, 169–185. [CrossRef ]

8. Iyer, A.K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for

tumor targeting. Drug Discov. Today 2006, 11, 812–818. [CrossRef ] [PubMed ]

9. Gatti, L.; Sevko, A.; de Cesare, M.; Arrighetti, N.; Manenti, G.; Ciusani, E.; Verderio, P.; Ciniselli, C.M.;

Cominetti, D.; Carenini, N.; et al. Histone deacetylase inhibitor-temozolomide co-treatment inhibits

melanoma growth through suppr ession of Chemokine (C-C motif) ligand 2-driven signals. Oncotarget

2

014, 5, 4516–4528. [CrossRef ] [PubMed ]

9

0. Sau, S.; Banerjee, R. Cationic lipid-conjugated dexamethasone as a selective antitumor agent. Eur. J. Med.

Chem. 2014, 83, 433–447. [CrossRef ] [PubMed ]

1. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer , R. Nanocarriers as an emerging platform

for cancer therapy. Nat. Nanotechnol. 2007, 2, 751–760. [CrossRef ] [PubMed ]

2. Sau, S.; Alsaab, H.O.; Kashaw, S.K.; Tatiparti, K.; Iyer, A.K. Advances in antibody?drug conjugates: A new

era of targeted cancer therapy. Drug Discov. Today 2017. [CrossRef ] [PubMed ]

3. He, X.M.; Carter , D.C. Atomic structure and chemistry of human serum albumin. Nature 1992, 358, 209–215.

[CrossRef ] [PubMed ]

4. Langer, K.; Balthasar, S.; Vogel, V.; Dinauer, N.; von Briesen, H.; Schubert, D. Optimization of the preparation

process for human serum albumin (HSA) nanoparticles. Int. J. Pharm. 2003, 257, 169–180. [CrossRef ]

5. Trerè, D.; Fiume, L.; De Giorgi, L.B.; Di Stefano, G.; Migaldi, M.; Derenzini, M. The asialoglycoprotein

receptor in human hepatocellular carcinomas: Its expression on proliferating cells. Br. J. Cancer 1999, 81,

4

04–408. [CrossRef ] [PubMed ]

9

1

6. Weber, C.; Reiss, S.; Langer, K. Preparation of surface modiﬁed protein nanoparticles by introduction of

sulfhydryl groups. Int. J. Pharm. 2000, 211, 67–78. [CrossRef ]

7. Petitpas, I.; Bhattacharya, A.A.; Twine, S.; East, M.; Curry, S. Crystal structure analysis of warfarin binding to

human serum albumin. Anatomy of drug site I. J. Biol. Chem. 2001, 276, 22804–22809. [CrossRef ] [PubMed ]

8. Elzoghby, A.O.; Samy, W.M.; Elgindy, N.A. Albumin-based nanoparticles as potential controlled release drug

delivery systems. J. Control. Release 2012, 157, 168–182. [CrossRef ] [PubMed ]

9. Elsadek, B.; Kratz, F. Impact of albumin on drug delivery—New applications on the horizon. J. Control.

Release 2012, 157, 4–28. [CrossRef ] [PubMed ]

00. Rhaese, S.; Von Briesen, H.; Rübsamen-Waigmann, H.; Kreuter, J.; Langer, K. Human serum

albumin-polyethylenimine nanoparticles for gene delivery. J. Control. Release 2003, 92, 199–208. [CrossRef ]

01. Simoes, S.; Slepushkin, V.; Pires, P.; Gaspar, R.; Pedroso de Lima, M.C.; Düzgüne s¸ , N. Human serum albumin

enhances DNA transfection by lipoplexes and confers resistance to inhibition by serum. Biochim. Biophys.

Acta 2000, 1463, 459–469. [CrossRef ]

1

02. Larsen, M.T.; Kuhlmann, M.; Hvam, M.L.; Howard, K.A. Albumin-based drug delivery: Harnessing nature

to cure disease. Mol. Cell. Ther. 2016, 4, 3. [CrossRef ] [PubMed ]

1

03. Fonseca, D.P.; Khalil, N.M.; Mainardes, R.M. Bovine serum albumin-based nanoparticles containing

resveratrol: Characterization and antioxidant activity. J. Drug Deliv. Sci. Technol. 2017, 39, 147–155.

[CrossRef ]

1

04. Švastová, E.; Hulíková, A.; Rafajová, M.; Zat’Ovi cˇ ová, M.; Gibadulinová, A.; Casini, A.; Cecchi, A.;

Scozzafava, A.; Supuran, C.T.; Pastorek, J.; et al. Hypoxia activates the capacity of tumor -associated

carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004, 577, 439–445. [CrossRef ] [PubMed ]

Int. J. Mol. Sci. 2018, 19, 838

20 of 21

1

05. Pastorekova, S.; Pastorek, J. Carbonic Anhydrase, Its Inhibitors and Activators; CRC Press: Boca Raton, FL,

USA, 2004.

06. Pastorek, J.; Pastorekova, S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From

biology to clinical use. Semin. Cancer Biol. 2015, 31, 52–64. [CrossRef ] [PubMed ]

07. Sneddon, D.; Poulsen, S.A. Agents described in the Molecular Imaging and Contrast Agent Database for

imaging carbonic anhydrase IX expression. J. Enzym. Inhib. Med. Chem. 2014, 29, 753–763. [CrossRef ]

[PubMed ]

1

08. Tafreshi, N.K.; Lloyd, M.C.; Bui, M.M.; Gillies, R.J.; Morse, D.L. Chapter 13: Carbonic Anhydrase IX

as an Imaging and Therapeutic Target for Tumors and Metastases. In Carbonic Anhydrase: Mechanism,

Regulation, Links to Disease, and Industrial Applications; Springer: Dordrecht, The Netherlands, 2014; Volume 75,

pp. 221–254, ISBN 978-94-007-7358-5.

1

09. Mohan, R.; Banerjee, M.; Ray, A.; Manna, T.; Wilson, L.; Owa, T.; Bhattacharyya, B.; Panda, D. Antimitotic

sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation. Biochemistry 2006, 45,

5

440–5449. [CrossRef ] [PubMed ]

1

10. Owa, T.; Yoshino, H.; Okauchi, T.; Yoshimatsu, K.; Ozawa, Y.; Sugi, N.H.; Nagasu, T.; Koyanagi, N.; Kitoh, K.

Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J. Med. Chem. 1999, 42,

3

789–3799. [CrossRef ] [PubMed ]

1

11. Schrier, R.W. Renal and Electrolyte Disorders; Little Brown and Co.: Boston, MA, USA, 1976.

12. Chegwidden, W.R.; Spencer, I. Sulfonamide inhibitors of carbonic anhydrase inhibit the growth of human

lymphoma cells in culture. Inﬂammopharmacology 1995, 3, 231–239. [CrossRef ]

1

13. Gradishar, W.J. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin. Pharmacother. 2006, 7,

1

041–1053. [CrossRef ] [PubMed ]

®

14. Stinchcombe, T.E. Nanoparticle albumin-bound paclitaxel: A novel Cremphor-EL -free formulation of

paclitaxel. Nanomedicine 2007, 2, 415–423. [CrossRef ] [PubMed ]

15. Liggins, R.T.; Hunter, W.L.; Burt, H.M. Solid-state characterization of paclitaxel. J. Pharm. Sci. 1997, 86,

1

458–1463. [CrossRef ] [PubMed ]

1

16. Perez, E. Paclitaxel in Breast Cancer. Oncologist 1998, 3, 373–389. [PubMed ]

17. Weaver, B.A. How Taxol/paclitaxel kills cancer cells. Mol. Biol. Cell 2014, 25, 2677–2681. [CrossRef ] [PubMed ]

18. Ledaki, I.; McIntyre, A.; Wigﬁeld, S.; Buffa, F.; McGowan, S.; Baban, D.; Li, J.; Harris, A.L.; Ledaki, I.;

McIntyre, A.; et al. Carbonic anhydrase IX induction deﬁnes a heterogeneous cancer cell response to hypoxia

and mediates stem cell-like properties and sensitivity to HDAC inhibition. Oncotarget 2015, 6, 19413–19427.

[

CrossRef ] [PubMed ]

19. Triantafyllou, A.; Liakos, P.; Tsakalof, A.; Georgatsou, E.; Simos, G.; Bonanou, S. Cobalt induces

hypoxia-inducible factor-1 (HIF-1 ) in HeLa cells by an iron-independent, but ROS-, PI-3K- and

1

α

MAPK-dependent mechanism. Free Radic. Res. 2006, 40, 847–856. [CrossRef ] [PubMed ]

1

20. Mukherjee, S.; Sau, S.; Madhuri, D.; Bollu, V.S.; Madhusudana, K.; Sreedhar, B.; Banerjee, R.; Patra, C.R.

Green synthesis and characterization of monodispersed gold nanoparticles: Toxicity study, delivery of

doxorubicin and its bio-distribution in mouse model. J. Biomed. Nanotechnol. 2016, 12, 165–181. [CrossRef ]

[

PubMed ]

21. Moses, J.E.; Moorhouse, A.D. The growing applications of click chemistry. Chem. Soc. Rev. 2007, 36,

249–1262. [CrossRef ] [PubMed ]

22. Lutz, J.F.; Zarafshani, Z. Efﬁcient construction of therapeutics, bioconjugates, biomaterials and bioactive

surfaces using azide-alkyne “click” chemistry. Adv. Drug Deliv. Rev. 2008, 60, 958–970. [CrossRef ] [PubMed ]

23. Tafreshi, N.K.; Lloyd, M.C.; Proemsey, J.B.; Bui, M.M.; Kim, J.; Gillies, R.J.; Morse, D.L. Evaluation of CAIX

and CAXII expression in breast cancer at varied O2Levels: CAIX is the superior surrogate imaging biomarker

of tumor hypoxia. Mol. Imaging Biol. 2016, 18, 219–231. [CrossRef ] [PubMed ]

1

24. Holliday, D.L.; Speirs, V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011

3, 215. [CrossRef ] [PubMed ]

25. Srinivasarao, M.; Galliford, C.V.; Low, P.S. Principles in the design of ligand-tar geted cancer therapeutics

and imaging agents. Nat. Rev. Drug Discov. 2015, 14, 203–219. [CrossRef ] [PubMed ]

26. Xu, S.; Olenyuk, B.Z.; Okamoto, C.T.; Hamm-Alvarez, S.F. Targeting receptor-mediated endocytotic pathways

with nanoparticles: Rationale and advances. Adv. Drug Deliv. Rev. 2013, 65, 121–138. [CrossRef ] [PubMed ]

,

1

Int. J. Mol. Sci. 2018, 19, 838

21 of 21

1

27. Yoo, H.S.; Park, T.G. Folate-receptor-targeted delivery of doxorubicin nano-aggr egates stabilized by

doxorubicin-PEG-folate conjugate. J. Control. Release 2004, 100, 247–256. [CrossRef ] [PubMed ]

28. Pastorekova, S.; Zatovicova, M.; Pastorek, J. Cancer -associated carbonic anhydrases and their inhibition.

Curr. Pharm. Des. 2008, 14, 685–698. [CrossRef ] [PubMed ]

29. Winum, J.-Y.; Scozzafava, A.; Montero, J.-L.; Supuran, C.T. Inhibition of carbonic anhydrase IX: A new

strategy against cancer. Anticancer Agents Med. Chem. 2009, 9, 693–702. [CrossRef ] [PubMed ]

30. Supuran, C.T. Carbonic anhydrase inhibitors. Bioorg. Med. Chem. Lett. 2010, 20, 3467–3474. [CrossRef ]

[PubMed ]

31. Winum, J.Y.; Rami, M.; Scozzafava, A.; Montero, J.L.; Supuran, C. Carbonic anhydrase IX: A new druggable

target for the design of antitumor agents. Med. Res. Rev. 2008, 28, 445–463. [CrossRef ] [PubMed ]

32. Supuran, C.; Briganti, F.; Tilli, S.; Chegwidden, W.; Scozzafava, A. Carbonic anhydrase inhibitors:

Sulfonamides as antitumor agents? Bioorg. Med. Chem. 2001, 9, 703–714. [CrossRef ]

33. Panda, D. Antimitotic sulfonamide inhibit microtubule assembly dynamics & anticancer. Biochemistry 2006

5, 5440.

,

4

34. Galisteo-González, F.; Molina-Bolívar, J.A. Systematic study on the preparation of BSA nanoparticles. Colloids

Surf. B Biointerfaces 2014, 123, 286–292. [CrossRef ] [PubMed ]

35. Jithan, A.; Madhavi, K.; Madhavi, M.; Prabhakar, K. Preparation and characterization of albumin

nanoparticles encapsulating curcumin intended for the treatment of breast cancer. Int. J. Pharm. Investig.

2

011, 1, 119–125. [CrossRef ] [PubMed ]

1

36. Lock, F.E.; McDonald, P.C.; Lou, Y.; Serrano, I.; Chafe, S.C.; Ostlund, C.; Aparicio, S.; Winum, J.Y.;

Supuran, C.T.; Dedhar, S. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the

hypoxic niche. Oncogene 2013, 32, 5210–5219. [CrossRef ] [PubMed ]

¯

37. Ivanova, L.; Zandberga, E.; Sili

n

,

a, K.; Kalni

n

,

a, Z.; Abols, A.; Endzelinš, E.; Vendina, I.; Romanchikova, N.;

,

Hegmane, A.; Trapencieris, P.; et al. Prognostic relevance of carbonic anhydrase IX expression is distinct in

various subtypes of breast cancer and its silencing suppr esses self-renewal capacity of breast cancer cells.

Cancer Chemother. Pharmacol. 2015, 75, 235–246. [CrossRef ] [PubMed ]

©

2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access

article distributed under the terms and conditions of the Creative Commons Attribution

CC BY) license (http://creativecommons.org/licenses/by/4.0/).

(

Article Doi

Copper-free ‘click’ chemistry-based synthesis and characterization of carbonic anhydrase-IX anchored albumin-paclitaxel nanoparticles for targeting tumor hypoxia

DOI: 10.3390/ijms19030838

Source and publish data:

Authors:

Article abstract of DOI:10.3390/ijms19030838

Full text of DOI:10.3390/ijms19030838

Products guided by the article

R&D Labs maybe for 14949-00-9

Relevant to this article

Hot Product